Altitude is a post-market 1000-patient global registry to assess clinical outcomes of the AlturaTM endograft system for endovascular repair of infra-renal abdominal aortic aneurysms in a real-world population. All patients in this study are already planned to be treated with AlturaTM, and this study is designed to capture outcomes in a formalised system.

The CE-marked AlturaTM system has been designed to simplify the procedure for repairing aneurysms endovascularly. Multiple clinical centres around the world will be involved to include a broad range of experience in a wide geographical span with initial enrolment focused on the UK with roll out into Europe during 2017 and globally from 2018.

Enrolment will be of consecutive eligible patients undergoing treatment with the AlturaTM system at each site, over a 2-year period, and all subjects will be followed procedurally to discharge, and according to institutional standard of care to 5 years’ post implant.

It is intended that by studying a real-world patient population in a multi-centre setting will provide an assessment of the generalisability of both approach and system